The effectiveness of disabling BER by the use of PARP inhibitors for treatment in conjunction with alkylatin therapy for glioblastoma and for other tumors as well is not clear, however several clinical trials are ongoing (http://www.clinicaltrials.gov) [62,63]. The gene discussed is PARP1; the disease is glioblastoma.